View in EDS

Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection

Saved in:
Bibliographic Details
Title: Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection
Authors: Mariusz Łucejko, Robert Flisiak, Anna Parfieniuk-Kowerda
Source: Expert Opinion on Pharmacotherapy. 17:1153-1164
Publisher Information: Informa UK Limited, 2016.
Publication Year: 2016
Subject Terms: Cyclopropanes, 0301 basic medicine, Macrocyclic Compounds, Proline, chronic - drug therapy, Antiviral agents - therapeutic use, Lactams, Macrocyclic, Antiviral Agents, Uracil - analogs & derivatives, Macrocyclic compounds - therapeutic use, 03 medical and health sciences, Sulfonamides - therapeutic use, 2-Naphthylamine, Sulfonamides - pharmacology, Ritonavir - therapeutic use, Humans, Anilides, Uracil, Sulfonamides, 0303 health sciences, Uracil - pharmacology, Ritonavir, Carbamates - pharmacology, Valine, Macrocyclic compounds - pharmacology, Hepatitis C, Chronic, Hepatitis C, 3. Good health, Ritonavir - pharmacology, combination - methods, Carbamates - therapeutic use, Anilides - therapeutic use, Drug Therapy, Combination, Drug therapy, Carbamates, Anilides - pharmacology, Antiviral agents - pharmacology, Uracil - therapeutic use
Description: Long lasting hepatocytes damage related to HCV infection stimulates liver fibrosis resulting in cirrhosis, hepatic failure and hepatocellular carcinoma. Until 2011 the only therapeutic option was 24-48 weeks of pegylated interferon alfa and ribavirin (RBV) with efficacy of 40-70%. New generation of direct-acting antivirals (DAA), available from 2014, can be combined and improve efficacy above 90% with 12 weeks of treatment.In this article we describe the first registered all-oral regimen consisting of three DAA - ombitasvir (OBV), paritaprevir (PTV) and dasabuvir (DSV) that became available in EU in 2015 to cure patients infected with HCV genotype 1 and 4. We performed a literature search focusing on efficacy and safety data from Phase 1-3 clinical studies and few real-world data.OBV/PTV/r±DSV±RBV provided an opportunity to cure almost all patients including cirrhotics and non-responders to previous therapy. This treatment is currently recommended as a first line regimen. However, there is still a need for real-world data. In coming years this medication will probably be replaced with the next DAA generation with improved characteristics such as a shorter treatment duration, improved safety and resistance profile.
Document Type: Article
Language: English
ISSN: 1744-7666
1465-6566
DOI: 10.1080/14656566.2016.1176143
Access URL: https://pubmed.ncbi.nlm.nih.gov/27064432
https://www.tandfonline.com/doi/full/10.1080/14656566.2016.1176143
http://europepmc.org/abstract/MED/27064432
Accession Number: edsair.doi.dedup.....3bc3a8c0042c844cf6ad7980f6fd7619
Database: OpenAIRE
Description
Abstract:Long lasting hepatocytes damage related to HCV infection stimulates liver fibrosis resulting in cirrhosis, hepatic failure and hepatocellular carcinoma. Until 2011 the only therapeutic option was 24-48 weeks of pegylated interferon alfa and ribavirin (RBV) with efficacy of 40-70%. New generation of direct-acting antivirals (DAA), available from 2014, can be combined and improve efficacy above 90% with 12 weeks of treatment.In this article we describe the first registered all-oral regimen consisting of three DAA - ombitasvir (OBV), paritaprevir (PTV) and dasabuvir (DSV) that became available in EU in 2015 to cure patients infected with HCV genotype 1 and 4. We performed a literature search focusing on efficacy and safety data from Phase 1-3 clinical studies and few real-world data.OBV/PTV/r±DSV±RBV provided an opportunity to cure almost all patients including cirrhotics and non-responders to previous therapy. This treatment is currently recommended as a first line regimen. However, there is still a need for real-world data. In coming years this medication will probably be replaced with the next DAA generation with improved characteristics such as a shorter treatment duration, improved safety and resistance profile.
ISSN:17447666
14656566
DOI:10.1080/14656566.2016.1176143